Marshall Wace LLP Boosts Holdings in Silence Therapeutics plc (NASDAQ:SLN)

Marshall Wace LLP boosted its position in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 190.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 488,889 shares of the company's stock after buying an additional 320,472 shares during the quarter. Marshall Wace LLP owned approximately 1.63% of Silence Therapeutics worth $3,364,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in shares of Silence Therapeutics by 609.2% during the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company's stock valued at $42,000 after acquiring an additional 5,233 shares during the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Silence Therapeutics in the fourth quarter valued at approximately $120,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Silence Therapeutics in the fourth quarter valued at approximately $69,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of Silence Therapeutics in the fourth quarter valued at approximately $134,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Silence Therapeutics in the fourth quarter valued at approximately $26,000. 98.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. HC Wainwright restated a "buy" rating and set a $75.00 price target on shares of Silence Therapeutics in a research report on Friday, March 7th. The Goldman Sachs Group lowered their price target on Silence Therapeutics from $6.00 to $4.00 and set a "sell" rating for the company in a research report on Tuesday, March 4th. Morgan Stanley lowered their price target on Silence Therapeutics from $49.00 to $45.00 and set an "overweight" rating for the company in a research report on Wednesday, March 5th. Finally, BMO Capital Markets decreased their target price on Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating for the company in a report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $40.67.

Silence Therapeutics Stock Performance

Silence Therapeutics stock traded up $0.14 during midday trading on Monday, reaching $3.50. The company's stock had a trading volume of 231,155 shares, compared to its average volume of 295,782. Silence Therapeutics plc has a fifty-two week low of $1.97 and a fifty-two week high of $24.38. The stock's 50 day simple moving average is $3.56 and its 200 day simple moving average is $7.32. The firm has a market capitalization of $104.76 million, a PE ratio of -2.23 and a beta of 1.25.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.